Targeted therapies in breast cancer: are heart and vessels also being targeted?

Breast Cancer Research

Table 2 Rates of severe congestive heart failure in trastuzumab adjuvant trials

	HERA [15]		NSABP B-31 [111]			N9831 [16]			BCIRG 006 [112]		PACS-04 [113]
Treatment arms	Obs	1-year H	AC → P	AC → PH	AC → P	AC → P → H	AC → PH	AC → D	AC → DH	DCb +H	Obs	1- year H
Women at risk (n)	1,698	1,703	872	932	767	718	875	1,050	1,068	1,056	268	260
Cardiac deaths	1	0	1	0	1	1	0	0	0	0	0	0
CHF NYHA class 3-4 (%)	0	13 (0.8)	9 (1.3)	35 (3.9)	2 (0.3)	18 (2.8)	19 (3.3)	4 (0.38)	20 (1.87)	4 (0.38)	1 (0.4)	4 (1.7)

NSABP B-31, cumulative incidence at 5 years; N9831, cumulative incidence at 3 years; no CHF class 3-4 and no cardiac death reported in the FinHer trial. AC, doxorubicin and cyclophosphamide; BCIRG, Breast Cancer International Research Group; Cb, carboplatin; CHF, congestive heart failure; D, docetaxel; H, Herceptin^® (trastuzumab); HERA, HERceptin Adjuvant; NSABP, National Surgical Adjuvant Breast and Bowel Project; NYHA, New York Heart Association; Obs, observation; P, paclitaxel; PACS, Protocole Adjuvant dans le cancer du sein.

ISSN: 1465-542X